X4 Pharmaceuticals Stock Fundamentals
| XFOR Stock | USD 0.34 0.02 6.25% |
X4 Pharmaceuticals fundamentals help investors to digest information that contributes to X4 Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of XFOR Stock. The fundamental analysis module provides a way to measure X4 Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to X4 Pharmaceuticals stock.
At this time, X4 Pharmaceuticals' Interest Income is relatively stable compared to the past year. As of 03/15/2025, Interest Expense is likely to grow to about 7 M, while Selling General Administrative is likely to drop slightly above 19.2 M. XFOR | Select Account or Indicator |
X4 Pharmaceuticals Company Shares Owned By Insiders Analysis
X4 Pharmaceuticals' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current X4 Pharmaceuticals Shares Owned By Insiders | 1.27 % |
Most of X4 Pharmaceuticals' fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, X4 Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 1.267% of X4 Pharmaceuticals are shares owned by insiders. This is 91.65% lower than that of the Biotechnology sector and 91.06% lower than that of the Health Care industry. The shares owned by insiders for all United States stocks is 87.44% higher than that of the company.
X4 Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining X4 Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare X4 Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across X4 Pharmaceuticals competition to find correlations between indicators driving X4 Pharmaceuticals's intrinsic value. More Info.X4 Pharmaceuticals is rated second in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, X4 Pharmaceuticals' Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value X4 Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.XFOR Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses X4 Pharmaceuticals' direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of X4 Pharmaceuticals could also be used in its relative valuation, which is a method of valuing X4 Pharmaceuticals by comparing valuation metrics of similar companies.X4 Pharmaceuticals is currently under evaluation in shares owned by insiders category among its peers.
XFOR Fundamentals
| Return On Equity | -0.26 | ||||
| Return On Asset | -0.47 | ||||
| Operating Margin | (61.61) % | ||||
| Current Valuation | 1.23 M | ||||
| Shares Outstanding | 170.55 M | ||||
| Shares Owned By Insiders | 1.27 % | ||||
| Shares Owned By Institutions | 59.18 % | ||||
| Number Of Shares Shorted | 11.06 M | ||||
| Price To Book | 0.91 X | ||||
| Price To Sales | 51.65 X | ||||
| Gross Profit | 628 K | ||||
| EBITDA | (107.1 M) | ||||
| Net Income | (101.17 M) | ||||
| Cash And Equivalents | 47.38 M | ||||
| Cash Per Share | 0.69 X | ||||
| Total Debt | 58.28 M | ||||
| Debt To Equity | 1.28 % | ||||
| Current Ratio | 2.39 X | ||||
| Book Value Per Share | 0.35 X | ||||
| Cash Flow From Operations | (96.51 M) | ||||
| Short Ratio | 1.59 X | ||||
| Earnings Per Share | (0.08) X | ||||
| Target Price | 3.13 | ||||
| Number Of Employees | 143 | ||||
| Beta | 0.39 | ||||
| Market Capitalization | 58 M | ||||
| Total Asset | 147.26 M | ||||
| Retained Earnings | (477.9 M) | ||||
| Working Capital | 99.21 M | ||||
| Net Asset | 147.26 M |
About X4 Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze X4 Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of X4 Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of X4 Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 847.5 K | 1.2 M | |
| Cost Of Revenue | 2.3 M | 2.4 M | |
| Stock Based Compensation To Revenue | 1.63 | 1.37 | |
| Sales General And Administrative To Revenue | 6.28 | 4.90 | |
| Research And Ddevelopement To Revenue | 12.58 | 9.13 | |
| Capex To Revenue | 0.41 | 0.43 | |
| Revenue Per Share | 0.17 | 0.16 | |
| Ebit Per Revenue | (22.95) | (24.10) |
Pair Trading with X4 Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if X4 Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in X4 Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against XFOR Stock
| 0.68 | IVA | Inventiva Sa | PairCorr |
| 0.56 | PBH | Prestige Brand Holdings | PairCorr |
| 0.53 | LLY | Eli Lilly | PairCorr |
| 0.49 | VIGL | Vigil Neuroscience | PairCorr |
| 0.42 | MGTX | MeiraGTx Holdings PLC Downward Rally | PairCorr |
The ability to find closely correlated positions to X4 Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace X4 Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back X4 Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling X4 Pharmaceuticals to buy it.
The correlation of X4 Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as X4 Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if X4 Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for X4 Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for XFOR Stock Analysis
When running X4 Pharmaceuticals' price analysis, check to measure X4 Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy X4 Pharmaceuticals is operating at the current time. Most of X4 Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of X4 Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move X4 Pharmaceuticals' price. Additionally, you may evaluate how the addition of X4 Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.